-
Something wrong with this record ?
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update
M. Rouprêt, M. Babjuk, M. Burger, O. Capoun, D. Cohen, EM. Compérat, NC. Cowan, JL. Dominguez-Escrig, P. Gontero, A. Hugh Mostafid, J. Palou, B. Peyronnet, T. Seisen, V. Soukup, RJ. Sylvester, BWGV. Rhijn, R. Zigeuner, SF. Shariat
Language English Country Switzerland
Document type Journal Article, Practice Guideline
- MeSH
- Carcinoma, Transitional Cell diagnosis therapy MeSH
- Kidney Pelvis * MeSH
- Humans MeSH
- Kidney Neoplasms diagnosis therapy MeSH
- Ureteral Neoplasms diagnosis therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
CONTEXT: The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract carcinoma, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, adjuvant treatment, instillation, recurrence, risk factors, and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification as well as for radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumour and two functional kidneys. After radical nephroureterectomy, cisplatin-based chemotherapy is indicated in locally advanced UTUC. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
Department of Radiology The Queen Alexandra Hospital Portsmouth UK
Department of Urology Caritas St Josef Medical Center University of Regensburg Regensburg Germany
Department of Urology Comprehensive Cancer Centre Medical University of Vienna Vienna Austria
Department of Urology Fundacio Puigvert Universidad Autonoma de Barcelona Barcelona Spain
Department of Urology Medical University of Graz Graz Austria
Department of Urology Medical University of Vienna Vienna Austria
Department of urology university of Rennes Rennes France
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Molinette Hospital University of Torino School of Medicine Torino Italy
EAU Guidelines Office Arnhem The Netherlands
Royal Surrey Hospital Guildford UK
Urology Fundación Instituto Valenciano de Oncología Valencia Spain
Urology Royal Free London NHS Foundation Trust Royal Free Hospital London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026245
- 003
- CZ-PrNML
- 005
- 20211026133059.0
- 007
- ta
- 008
- 211013s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2020.05.042 $2 doi
- 035 __
- $a (PubMed)32593530
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Rouprêt, Morgan $u Urology, GRC n°5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France. Electronic address: morgan.roupret@aphp.fr
- 245 10
- $a European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update / $c M. Rouprêt, M. Babjuk, M. Burger, O. Capoun, D. Cohen, EM. Compérat, NC. Cowan, JL. Dominguez-Escrig, P. Gontero, A. Hugh Mostafid, J. Palou, B. Peyronnet, T. Seisen, V. Soukup, RJ. Sylvester, BWGV. Rhijn, R. Zigeuner, SF. Shariat
- 520 9_
- $a CONTEXT: The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract carcinoma, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, adjuvant treatment, instillation, recurrence, risk factors, and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification as well as for radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumour and two functional kidneys. After radical nephroureterectomy, cisplatin-based chemotherapy is indicated in locally advanced UTUC. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
- 650 _2
- $a karcinom z přechodných buněk $x diagnóza $x terapie $7 D002295
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x diagnóza $x terapie $7 D007680
- 650 12
- $a ledvinná pánvička $7 D007682
- 650 _2
- $a nádory močovodu $x diagnóza $x terapie $7 D014516
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Babjuk, Marko $u Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Burger, Maximilian $u Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Capoun, Otakar $u Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Cohen, Daniel $u Urology, Royal Free London-NHS Foundation Trust, Royal Free Hospital, London, UK
- 700 1_
- $a Compérat, Eva M $u Department of Pathology, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Hopital Tenon, Paris, France
- 700 1_
- $a Cowan, Nigel C $u Department of Radiology, The Queen Alexandra Hospital, Portsmouth, UK
- 700 1_
- $a Dominguez-Escrig, Jose L $u Urology, Fundación Instituto Valenciano de Oncología (I.V.O.), Valencia, Spain
- 700 1_
- $a Gontero, Paolo $u Division of Urology, Molinette Hospital, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Hugh Mostafid, A $u Royal Surrey Hospital, Guildford, UK
- 700 1_
- $a Palou, Joan $u Department of Urology, Fundacio Puigvert, Universidad Autonoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Peyronnet, Benoit $u Department of urology, university of Rennes, Rennes, France
- 700 1_
- $a Seisen, Thomas $u Urology, GRC n°5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France
- 700 1_
- $a Soukup, Viktor $u Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Sylvester, Richard J $u EAU Guidelines Office, Arnhem, The Netherlands
- 700 1_
- $a Rhijn, Bas W G van $u Department of Urology, Caritas-St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Zigeuner, Richard $u Department of Urology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Urology Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 79, č. 1 (2021), s. 62-79
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32593530 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133105 $b ABA008
- 999 __
- $a ok $b bmc $g 1715072 $s 1146752
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 79 $c 1 $d 62-79 $e 20200624 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20211013
